drugset / Trial / NCT04175847
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This was a multicenter, open, multi-cohort extended PHASE I/IIa study, consisting of 2 phases:Phase I (Phase I dose escalation) and Phase II (Phase IIa multi-cohort extension). The objective of this study was to evaluate safety, tolerability, pharmacokinetic characteristics, and initial efficacy in malignant pleural mesothelioma and MSLN in advanced malignant solid tumors.
Timeline
- Start
- 2020-04-14
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC88 | Unknown | 0.1 mg/kg | — |
| Subject | RC88 | Unknown | 0.5 mg/kg | — |
| Subject | RC88 | Unknown | 1 mg/kg | — |
| Subject | RC88 | Unknown | 1.5 mg/kg | — |
| Subject | RC88 | Unknown | 2 mg/kg | — |
| Subject | RC88 | Unknown | 2.5 mg/kg | — |